Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 17/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9292837 | 0.85 | KIF11 (0.64) | KIF11 | |
| SCHEMBL9016793 | 0.85 | KIF11 (0.64) | KIF11 | |
| SCHEMBL34785 | 0.83 | KIF11 (0.57) | KIF11DNMT1CYP2C19 | |
| SCHEMBL16358480 | 0.83 | KIF11 (0.54) | KIF11DNMT1 | |
| SCHEMBL12347301 | 0.83 | KIF11 (0.53) | KIF11DNMT1 | |
| SCHEMBL24396543 | 0.80 | KIF11 (0.47) | KIF11DNMT1 | |
| SCHEMBL16660583 | 0.80 | KIF11 (0.44) | KIF11DNMT1 | |
| SCHEMBL10503169 | 0.80 | KIF11 (0.42) | KIF11DNMT1 | |
| SCHEMBL12347279 | 0.80 | KIF11 (0.59) | KIF11 | |
| SCHEMBL1537242 | 0.79 | KIF11 (0.57) | KIF11FFAR1CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111793106-A | Polypeptide helix conformation stabilizing method | 安徽大学 | 2020-10-20 | — | — | CN | claimed |
| US-12594275-B2 | Immunophilin binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| US-12558356-B2 | Immunophilin binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250345444-A1 | CLEAVABLE FRAGMENT DIRECTED BY AFFINITY FRAGMENT, DESIGN AND SYNTHESIS THEREOF, AND USE THEREOF IN PREPARATION OF SITE-DIRECTED DRUG CONJUGATE | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2025-11-13 | — | — | US | disclosed |
| US-20250108052-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-03 | — | — | US | disclosed |
| CN-119591595-A | HDAC6 inhibitor, pharmaceutical composition and application | 四川大学华西医院 | 2025-03-11 | — | — | CN | disclosed |
| EP-4501945-A1 | CLEAVABLE FRAGMENT DIRECTED BY AFFINITY FRAGMENT, DESIGN AND SYNTHESIS THEREOF, AND USE THEREOF IN PREPARATION OF SITE-DIRECTED DRUG CONJUGATE | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2025-02-05 | — | — | EP | disclosed |
| CN-118696048-A | Camptothecin derivative, antibody-drug conjugate and pharmaceutical composition based on camptothecin derivative and application of camptothecin derivative | 同宜医药（苏州）有限公司 | 2024-09-24 | — | — | CN | disclosed |
| EP-4420730-A2 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | The Johns Hopkins University (US) | 2024-08-28 | — | — | EP | disclosed |
| EP-3964498-B1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-0777498-A1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996040756-A1 | RADIOMETAL-BINDING ANALOGUES OF LEUTENIZING HORMONE RELEASING HORMONE | IMMUNOMEDICS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5571825-A | Method of selectively inhibiting prostaglandin G/H synthase-2 | WARNER-LAMBERT COMPANY (US) | 1996-11-05 | — | — | US | disclosed |
| WO-1996002274-A1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-02-01 | — | — | WO | disclosed |
| US-5321000-A | Benzhydryl compounds as herbicide antidotes | MONSANTO COMPANY (US) | 1994-06-14 | — | — | US | disclosed |
| US-5011975-A | Novel (trans 1-propenyl)disulfide derivative and process for preparing the same | NIPPON MIKTRON LIMITED (JP) | 1991-04-30 | — | — | US | disclosed |
| US-4999424-A | Antigout and antitumor agents | THE PENNSYLVANIA STATE UNIVERSITY (US) | 1991-03-12 | — | — | US | disclosed |
| US-4964893-A | REDUCING INJURY TO A CROP PLANT | MONSANTO COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
| WO-1990005137-A1 | GAR TRANSFORMYLASE INHIBITOR | THE PENNSYLVANIA RESEARCH CORPORATION (US) | 1990-05-17 | — | — | WO | disclosed |
| US-4346187-A | AND ORGANIC BROMINE COMPOUND | BORG-WARNER CHEMICALS, INC. (US) | 1982-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594275-B2 | Immunophilin binding agents and uses thereof | CCR1, CCRL2, CCR3 | KIF11 3530/4885FFAR1 2160/4885DNMT1 4622/4885 |
| US-20250108052-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | SERPINA6, SELPLG, FABP7 | KIF11 3015/4885FFAR1 4726/4885DNMT1 4876/4885 |
| US-20250345444-A1 | CLEAVABLE FRAGMENT DIRECTED BY AFFINITY FRAGMENT, DESIGN AND SYNTHESIS THEREOF, AND USE THEREOF IN PREPARATION OF SITE-DIRECTED DRUG CONJUGATE | SPR, CPSF1, CPSF7 | KIF11 2631/4885FFAR1 2871/4885DNMT1 2713/4885 |
| US-12558356-B2 | Immunophilin binding agents and uses thereof | CCRL2, CFB, CCR3 | KIF11 3990/4885FFAR1 1590/4885DNMT1 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.